Q32 Bio Inc
Research Q32 Bio Inc (QTTB) on Bullrun: market cap USD 207.46M, P/E 2.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerQTTB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 207.46M
- P/E2.9
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 8.95M
- Free cash flow-USD 3.08M
Valuation Snapshot
latest market cap is USD 207.46M; P/E is 2.9.
Peer valuation comparison
Latest P/E is 2.91x versus a Healthcare sector median of 24.6x (88.2% below).
Latest P/E is 2.91x versus a United States median of 23.85x (87.8% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 53.74M | USD 29.80M | -USD 33.54M | n/a | 2.42 | USD 48.30M | USD 15.34M | USD 42.01M |
| FY2024 | USD 0 | -USD 47.70M | -USD 67.79M | n/a | -6.58 | USD 77.97M | USD 18.90M | USD 5.68M |
| FY2023 | USD 1.16M | -USD 53.70M | -USD 18.68M | n/a | -153.96 | USD 25.62M | USD 50.84M | -USD 182.92M |
| FY2022 | USD 3.21M | -USD 5.01M | -USD 114.95M | n/a | -0.09 | USD 33.99M | USD 44.73M | -USD 130.71M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 207.46M | 2.9 | n/a | n/a |
| 2025 | 2025-12-31 | USD 42.69M | 1.4 | n/a | n/a |
| 2024 | 2024-12-31 | USD 41.96M | n/a | n/a | n/a |
About Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Q32 Bio Inc's market cap?
Q32 Bio Inc's market capitalization is USD 207.46M.
What is Q32 Bio Inc's P/E ratio?
Q32 Bio Inc's price-to-earnings (P/E) ratio is 2.9.
What does Q32 Bio Inc do?
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.